Litcius/Paper detail

887O First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial

Éric Baudin, Thomas Walter, A. Beron, D. Smith, Julien Hadoux, C. Lachachi, David Taïeb, C. Ansquer, L.O. Dierickx, L. de Mestier du Bourg, Emmanuel Deshayes, E. Quak, L. Dahan, R. Guimbaud, Y. Touchefeu, M. Haissaguerre, C. Do Cao, C. Lombard Bohas, M. Attard, S. Foulon

2022Annals of Oncology45 citationsDOI

Topics & Concepts

MedicineClinical endpointInternal medicineProgression-free survivalNeuroendocrine tumorsResponse Evaluation Criteria in Solid TumorsSunitinibOncologyRadionuclide therapySurrogate endpointRandomized controlled trialGastroenterologyPhases of clinical researchClinical trialCancerChemotherapyNeuroendocrine Tumor Research AdvancesLung Cancer Research StudiesRadiopharmaceutical Chemistry and Applications
887O First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial | Litcius